Antibody titers quadruple in most trial subjects due to Sputnik Light and AstraZeneca combo in Azerbaijan - RDIF

MOSCOW. Sept 27 (Interfax) - The amount of coronavirus S protein-specific antibodies quadrupled or grew even more in most trial subjects inoculated with a combination of the Sputnik Light and AstraZeneca vaccines in Azerbaijan, the Russian Direct Investment Fund (RDIF) said in a statement on Monday.

"Data was collected from the first 20 participants of the study, who had received both components of the combination with AstraZeneca vaccine as the first component and Sputnik Light as the second one administered 29 days later. According to the results of the interim analysis, a fourfold or higher increase in neutralizing antibodies to the spike protein (S-protein) of the SARS-CoV-2 was found in 85% of the volunteers on the 57th day of the study," the RDIF said.

The AstraZeneca vaccine was administered as the first shot, and Sputnik Light served as the second shot, received 29 days later, it said.

The trials of the combined use of Sputnik Light and AstraZeneca currently involve 100 volunteers in Azerbaijan, the RDIF said.